Serveur d'exploration Covid et maladies cardiovasculaires

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.

Identifieur interne : 000177 ( Main/Exploration ); précédent : 000176; suivant : 000178

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.

Auteurs : Antonio Ceriello [Italie] ; Eberhard Standl [Allemagne] ; Doina Catrinoiu [Roumanie] ; Baruch Itzhak [Israël] ; Nebojsa M. Lalic [Serbie] ; Dario Rahelic [Croatie] ; Oliver Schnell [Allemagne] ; Jan Škrha [République tchèque] ; Paul Valensi

Source :

RBID : pubmed:32409501

Descripteurs français

English descriptors

Abstract

People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.

DOI: 10.2337/dc20-0941
PubMed: 32409501


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.</title>
<author>
<name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
<affiliation wicri:level="3">
<nlm:affiliation>IRCCS MultiMedica, Milan, Italy antonio.ceriello@hotmail.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
<wicri:regionArea>IRCCS MultiMedica, Milan</wicri:regionArea>
<placeName>
<settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
<affiliation wicri:level="3">
<nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta</wicri:regionArea>
<wicri:noRegion>Constanta</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Clalit Health Services and Technion Faculty of Medicine, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade</wicri:regionArea>
<wicri:noRegion>Belgrade</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<affiliation wicri:level="1">
<nlm:affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Zagreb School of Medicine, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:affiliation>University of Osijek School of Medicine, Osijek, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Osijek School of Medicine, Osijek</wicri:regionArea>
<wicri:noRegion>Osijek</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
<affiliation wicri:level="3">
<nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague</wicri:regionArea>
<placeName>
<settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32409501</idno>
<idno type="pmid">32409501</idno>
<idno type="doi">10.2337/dc20-0941</idno>
<idno type="wicri:Area/Main/Corpus">000277</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000277</idno>
<idno type="wicri:Area/Main/Curation">000277</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000277</idno>
<idno type="wicri:Area/Main/Exploration">000277</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.</title>
<author>
<name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
<affiliation wicri:level="3">
<nlm:affiliation>IRCCS MultiMedica, Milan, Italy antonio.ceriello@hotmail.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
<wicri:regionArea>IRCCS MultiMedica, Milan</wicri:regionArea>
<placeName>
<settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
<affiliation wicri:level="3">
<nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta</wicri:regionArea>
<wicri:noRegion>Constanta</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Clalit Health Services and Technion Faculty of Medicine, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
<affiliation wicri:level="1">
<nlm:affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade</wicri:regionArea>
<wicri:noRegion>Belgrade</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<affiliation wicri:level="1">
<nlm:affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Zagreb School of Medicine, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<nlm:affiliation>University of Osijek School of Medicine, Osijek, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Osijek School of Medicine, Osijek</wicri:regionArea>
<wicri:noRegion>Osijek</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
<affiliation wicri:level="3">
<nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague</wicri:regionArea>
<placeName>
<settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
</author>
</analytic>
<series>
<title level="j">Diabetes care</title>
<idno type="eISSN">1935-5548</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Blood Glucose (MeSH)</term>
<term>Blood Glucose Self-Monitoring (MeSH)</term>
<term>Cardiovascular Diseases (epidemiology)</term>
<term>Cardiovascular Diseases (therapy)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Diabetes Mellitus (drug therapy)</term>
<term>Diabetes Mellitus (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Risk Factors (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Autosurveillance glycémique (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Comorbidité (MeSH)</term>
<term>Coronavirus (effets des médicaments et des substances chimiques)</term>
<term>Diabète (traitement médicamenteux)</term>
<term>Diabète (épidémiologie)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Glycémie (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term>
<term>Maladies cardiovasculaires (thérapie)</term>
<term>Maladies cardiovasculaires (épidémiologie)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Angiotensin-Converting Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Diabetes Mellitus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Cardiovascular Diseases</term>
<term>Coronavirus Infections</term>
<term>Diabetes Mellitus</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Maladies cardiovasculaires</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Diabète</term>
<term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Diabète</term>
<term>Infections à coronavirus</term>
<term>Maladies cardiovasculaires</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Betacoronavirus</term>
<term>Blood Glucose</term>
<term>Blood Glucose Self-Monitoring</term>
<term>Comorbidity</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Autosurveillance glycémique</term>
<term>Betacoronavirus</term>
<term>Comorbidité</term>
<term>Facteurs de risque</term>
<term>Glycémie</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">32409501</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>06</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>06</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1935-5548</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>43</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes care</Title>
<ISOAbbreviation>Diabetes Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.</ArticleTitle>
<Pagination>
<MedlinePgn>1427-1432</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/dc20-0941</ELocationID>
<Abstract>
<AbstractText>People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.</AbstractText>
<CopyrightInformation>© 2020 by the American Diabetes Association.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ceriello</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000-0002-7955-4684</Identifier>
<AffiliationInfo>
<Affiliation>IRCCS MultiMedica, Milan, Italy antonio.ceriello@hotmail.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Standl</LastName>
<ForeName>Eberhard</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Catrinoiu</LastName>
<ForeName>Doina</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Itzhak</LastName>
<ForeName>Baruch</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lalic</LastName>
<ForeName>Nebojsa M</ForeName>
<Initials>NM</Initials>
<AffiliationInfo>
<Affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rahelic</LastName>
<ForeName>Dario</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>University of Osijek School of Medicine, Osijek, Croatia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schnell</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
<AffiliationInfo>
<Affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Škrha</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">0000-0002-2475-227X</Identifier>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine 3, First Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valensi</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>05</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diabetes Care</MedlineTA>
<NlmUniqueID>7805975</NlmUniqueID>
<ISSNLinking>0149-5992</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015190" MajorTopicYN="N">Blood Glucose Self-Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2020</Year>
<Month>04</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>5</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>5</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32409501</ArticleId>
<ArticleId IdType="pii">dc20-0941</ArticleId>
<ArticleId IdType="doi">10.2337/dc20-0941</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Croatie</li>
<li>Israël</li>
<li>Italie</li>
<li>Roumanie</li>
<li>République tchèque</li>
<li>Serbie</li>
</country>
<region>
<li>Bavière</li>
<li>Bohême centrale</li>
<li>District de Haute-Bavière</li>
<li>Lombardie</li>
</region>
<settlement>
<li>Milan</li>
<li>Munich</li>
<li>Prague</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
</noCountry>
<country name="Italie">
<region name="Lombardie">
<name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
</region>
</country>
<country name="Allemagne">
<region name="Bavière">
<name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
</region>
<name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
</country>
<country name="Roumanie">
<noRegion>
<name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
</noRegion>
</country>
<country name="Israël">
<noRegion>
<name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
</noRegion>
</country>
<country name="Serbie">
<noRegion>
<name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
</noRegion>
</country>
<country name="Croatie">
<noRegion>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
</noRegion>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
</country>
<country name="République tchèque">
<region name="Bohême centrale">
<name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000177 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000177 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CardioCovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32409501
   |texte=   Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32409501" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CardioCovidV1 

Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Aug 4 15:08:30 2020. Site generation: Wed Jan 27 11:23:02 2021